At a glance
ClinicalIndex Comparison Record- ✓Histologically proven stage I-III multiple myeloma
- ✓Less than 18 months since diagnosis
- ✓Responding or stable disease after induction therapy with no greater than 40% bone marrow involvement
- ✓Age 65 years or younger
- ✕Waldenstrom's macroglobulinemia
- ✕Prior malignancy within past 5 years except nonmelanomatous skin cancer or cervical carcinoma in situ
- ✕HIV positive
- ✕Hepatitis B antigen or hepatitis C RNA positive
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating filgrastim, recombinant interferon alfa, and 6 other interventions for Multiple Myeloma and Plasma Cell Neoplasm. Completed, enrolled 77 participants across 2 sites.
Detailed Summary
RATIONALE: Drugs used in chemotherapy work in different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells. Biological therapies, such as interferon alfa, use different ways to stimulate the immune system and stop cancer cells from growing. Thalidomide may stop the growth of cancer cells by stopping blood flow to the tumor. Pamidronate may help to reduce the side effects of treatment for multiple myeloma. PURPOSE: This phase II trial is studying combination chemotherapy, peripheral stem cell transplantation, biological therapy, pamidronate, and thalidomide to see how well they work in treating patients with stage I, stage II, or stage III multiple myeloma.